Aurobindo Pharma Limited — JV/Acquisition, 06-02-2025: Acquisition

Aurobindo Pharma has completed the acquisition of 80% equity share capital in Tergene Biotech Limited from its wholly-owned subsidiary, Auro Vaccines. This transaction aims to bring Tergene under direct control, enhancing operational oversight. Notably, Tergene has reported a negative net worth of ₹42.40 crores and generated no revenue over the last fiscal year. The acquisition, valued at ₹107.6 million, is expected to be finalized by February 28, 2025, without requiring any additional regulatory approvals. This strategic move aligns with Aurobindo's objective of streamlining its subsidiary structure.